FG-3019: Phase II started

FibroGen began an open-label, U.S. Phase II trial to evaluate 35 mg/kg IV FG-3019 every 2 weeks for up to 2 years in up to 22 non-ambulatory patients ages >=12. The antibody was developed using UltiMa...